Search results for "dermatology life quality index"

showing 8 items of 18 documents

The global burden of chronic urticaria for the patient and society*

2020

Chronic urticaria (CU) affects about 1% of the world population of all ages, mostly young and middle-aged women. It usually lasts for several years (> 1 year in 25-75% of patients) and often takes > 1 year before effective management is implemented. It presents as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) or both in the same person. More than 25% of cases are resistant to H1 -antihistamines, even at higher doses, and third- and fourth-line therapies (omalizumab and ciclosporin) control the disease only in two-thirds of H1 -antihistamine-resistant patients. Here we review the impact of CU on different aspects of patients' quality of life and the burden of this …

Pediatricsmedicine.medical_specialtyUrticariaOmalizumabDermatologyOmalizumabDisease030207 dermatology & venereal diseases03 medical and health sciencesIndirect costs0302 clinical medicineQuality of lifemedicineHumansChronic UrticariaDepression (differential diagnoses)business.industryUrticària -- TractamentDermatology Life Quality IndexMiddle AgedSalut públicaEuropeSexual dysfunctionQualitat de vidaChronic DiseasePresenteeismQuality of LifeIndicadors econòmicsFemalemedicine.symptombusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Differential Effects of Biologics on Psoriasis-Related Vascular Inflammation and Risk of Thrombosis

2020

Programa Estatal de I+D+i Orientada a los Retos de la Sociedad from Ministerio de Ciencia, Innovación y Universidades and European Regional Development Fund (Spain) [RTI2018-094436-B-I00]; Ministerio de Sanidad y Consumo CIBERehd (Spain) [CB06/04/0071]; Generalitat Valenciana (Spain) [PROMETEO/2018/141]; Proyectos Grupos Emergentes [GV/2019/043]; and Universidad Europea (Spain) (2018/UEM32 and 2019/UEM29]. 8.551 JCR (2020) Q1, 4/69 Dermatology 1.951 SJR (2020) Q1, 54/438 Biochemistry No data IDR 2020 UEV

Vasculitis0301 basic medicinemedicine.medical_specialtyEnfermedad cardiovascularImiquimodCell CommunicationDermatologyBiochemistryMiceTrombosis03 medical and health sciences0302 clinical medicinePsoriasis Area and Severity IndexPsoriasisProductos biológicosLeukocytesmedicineAnimalsHumansPsoriasisMolecular BiologyBody surface areaBiological ProductsImiquimodTumor Necrosis Factor-alphabusiness.industryEndothelial CellsThrombosisCell BiologyDermatology Life Quality Indexmedicine.diseaseDermatologyThrombosis030104 developmental biology030220 oncology & carcinogenesisMethotrexatebusinessEnfermedad de la pielMacemedicine.drugJournal of Investigative Dermatology
researchProduct

General quality of life of patients with acne vulgaris before and after performing selected cosmetological treatments

2017

Background Achieving a satisfying quality of life for a patient by applying individually matched therapy is, simultaneously, a great challenge and a priority for contemporary medicine. Patients with visible dermatological ailments are particularly susceptible to reduction in the general quality of life. Among the dermatological diseases, acne causes considerable reduction in the quality of life and changes in self-perception that lead to the worsening of a patient's mental condition, including depression and suicidal thoughts. As a result, difficulties in contact with loved ones, as well as social and professional problems are observed, which show that acne is not a somatic problem alone. T…

medicine.medical_specialtyActivities of daily livingAlternative medicineMedicine (miscellaneous)cosmetological treatments030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeacne vulgarisMedicine030212 general & internal medicinePharmacology Toxicology and Pharmaceutics (miscellaneous)AcneDepression (differential diagnoses)Original Researchbusiness.industryHealth PolicyDermatology Life Quality IndexPsychodermatologymedicine.diseaseDermatologyMesotherapyquality of lifebusinessSocial Sciences (miscellaneous)Patient Preference and Adherence
researchProduct

<p>Examining Quality of Life After Treatment with Azelaic and Pyruvic Acid Peels in Women with Acne Vulgaris</p>

2020

Purpose This randomized parallel study aims to investigate the azelaic acid (AA), and pyruvic acid (PA) peels treatment effect on health-related quality of life (QOL) in young adult women with acne vulgaris. Patients and Methods The participants were 120 female undergraduate students, with mild to moderate facial acne and an average age of 22 years old (M = 22.2, SD = 16.1). Eligibility criteria were as follows: female gender, 18-25 years of age, no dermatological treatment within the last 12 months and mild to moderate papulopustular acne. Patients were randomly divided into two groups, the first group was treated with AA, and the second group was treated with PA. Both groups received trea…

medicine.medical_specialtyAzelaic acidbusiness.industryParallel studyDermatologyDermatology Life Quality Indexmedicine.disease030207 dermatology & venereal diseases03 medical and health scienceschemistry.chemical_compound0302 clinical medicineQuality of lifePapulopustularchemistry030220 oncology & carcinogenesisInternal medicinemedicinePyruvic acidYoung adultbusinessAcnemedicine.drugClinical, Cosmetic and Investigational Dermatology
researchProduct

Quality-of-Life Impairment among Patients with Hidradenitis Suppurativa: A Cross-Sectional Study of 1795 Patients

2021

The chronic, inflammatory skin disorder hidradenitis suppurativa (HS) is associated well documented negative influences on patients&rsquo

medicine.medical_specialtyCross-sectional studyPopulationDiseaseDemographic dataArticleGeneral Biochemistry Genetics and Molecular Biology030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeInternal medicineMedicineHidradenitis suppurativa030212 general & internal medicineDLQIlcsh:ScienceeducationEcology Evolution Behavior and Systematicseducation.field_of_studyintegumentary systembusiness.industryhidradenitis suppurativaPaleontologyDermatology Life Quality Indexmedicine.diseasehumanitiesquality of lifeSpace and Planetary ScienceCohortlcsh:QbusinessLife
researchProduct

Impact of Intense Pulsed Light Therapy on the Quality of Life of Rosacea Patients

2018

Abstract Rosacea is a chronic inflammatory skin disorder affecting predominantly adult patients. The aim of the current investigation was to evaluate clinical response by using quality of life assessment before and after an IPL (intensive pulsed light) therapy course for patients sufferring from rosacea treated in the outpatient clinic “Health and Aesthetics” in Rīga during a one-year period (in 2016). All patients presented with typical clinical symptoms of rosacea on the face — acneiform papules, pustules, telangiectasia, centrofacial erythema, and complaints about flushing and burning. In the current study, 100 rosacea patients treated with IPL therapy were selected. Each patient filled …

medicine.medical_specialtyMultidisciplinaryGeneral interestintensive pulsed lightScienceQdermatology life quality indexmedicine.diseaseDermatologyrosaceaRosaceaphototypemedicineIntense Pulsed Light Therapysense organsProceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences.
researchProduct

Validation of the Angioedema Control Test (AECT)—A Patient-Reported Outcome Instrument for Assessing Angioedema Control

2019

Background Recurrent angioedema (RA) is an important clinical problem in routine care and emergency medicine. As of recently, the only validated tools to specifically assess disease status in patients with RA were diary-type activity assessments and angioedema-related quality-of-life questionnaires. Although these tools are particularly helpful in clinical studies, they were not designed to determine disease control or to guide treatment decisions. To close this gap, the Angioedema Control Test (AECT) was published recently. Objective To test the AECT for its validity and reliability, and to identify a cutoff value to aid treatment decisions. Methods Two AECT versions with a recall period o…

medicine.medical_specialtyPsychometricsIntraclass correlationValidity03 medical and health sciences0302 clinical medicineCronbach's alphaSurveys and QuestionnairesmedicineHumansImmunology and AllergyPatient Reported Outcome Measures030212 general & internal medicineAngioedemaAngioedemabusiness.industryReproducibility of ResultsDermatology Life Quality Indexmedicine.disease030228 respiratory systemConvergent validityHereditary angioedemaQuality of LifePhysical therapyPatient-reported outcomemedicine.symptombusinessThe Journal of Allergy and Clinical Immunology: In Practice
researchProduct

Evidence for a 'window of opportunity' in hidradenitis suppurativa treated with adalimumab: a retrospective, real-life multicentre cohort study

2021

BACKGROUND The anti-tumour necrosis factor (TNF)-α adalimumab is the only licenced biologic for moderate-to-severe hidradenitis suppurativa (HS). No predictors of response have been identified so far. OBJECTIVES To identify clinical parameters predicting response to adalimumab and confirm its efficacy/safety. METHODS The data of 389 patients with HS treated with adalimumab in 21 Italian centres were reviewed. Sex, age at onset/diagnosis/baseline, body mass index, smoking, phenotype, previous treatments, concomitant antibiotics and 'therapeutic delay', defined as the time from HS onset to adalimumab initiation, were assessed. Response to adalimumab and its impact on quality of life (QoL) wer…

medicine.medical_specialtyVisual analogue scaleAnti-Inflammatory AgentsDermatologySeverity of Illness Index030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSettore MED/35Quality of lifeInternal medicineSeverity of illnessmedicineAdalimumabHumansHidradenitis suppurativahidrosadenitis suppurativaRetrospective Studiesbusiness.industryAdalimumabRetrospective cohort studyOdds ratioDermatology Life Quality Indexmedicine.diseasehumanitiesHidradenitis SuppurativaTreatment OutcomeQuality of LifeAdalimumab Hidradenitis Suppurativa quality of lifeSettore MED/35 - MALATTIE CUTANEE E VENEREEbusinessmedicine.drug
researchProduct